Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shin Nippon Biomedical Laboratories’ subsidiary, Satsuma Pharmaceuticals, has resubmitted its New Drug Application for STS101, a treatment for acute migraine, to the FDA, addressing previous concerns about formulation while receiving no requests for additional clinical trials. This move is seen as pivotal in offering new options for migraine sufferers.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.